نتائج البحث - "Cinta Hierro"

1

HighFGFR1–4mRNA Expression Levels Correlate with Response to Selective FGFR Inhibitors in Breast Cancer

المصدر: Clinical Cancer Research. 28:137-149

مصطلحات موضوعية: CD31, Cancer Research, medicine.diagnostic_test, business.industry, Angiogenesis, Kinase, Fibroblast growth factor receptor 1, medicine.disease, Immunofluorescence, Metastatic breast cancer, Breast cancer, Oncology, Cancer research, Medicine, Immunohistochemistry, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_________::fc1a8b5bf78cd7165ed6c66557658b98
https://doi.org/10.1158/1078-0432.ccr-21-1810

2

A CT-based Radiomics Signature Is Associated with Response to Immune Checkpoint Inhibitors in Advanced Solid Tumors

المصدر: Radiology

مصطلحات موضوعية: Male, business.industry, Immune checkpoint inhibitors, Middle Aged, Reviews and Commentary, Immune system, Radiomics, Neoplasms, Biomarkers, Tumor, Cancer research, Humans, Medicine, Female, Radiology, Nuclear Medicine and imaging, Tomography, X-Ray Computed, business, Immune Checkpoint Inhibitors, Aged, Retrospective Studies

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a84a0de5a0c23c801321f32a69b0bf48
https://doi.org/10.1148/radiol.2021200928

3

Futibatinib, an Irreversible FGFR1–4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF/FGFR Aberrations: A Phase I Dose-Expansion Study

المؤلفون: Cinta Hierro, Hendrik-Tobias Arkenau, Lipika Goyal, Joon Oh Park, Funda Meric-Bernstam, Marc Sanson, Robin Kate Kelley, Yaohua He, Karim A. Benhadji, John Bridgewater, Milind Javle, Rastislav Bahleda, Ben Tran

المساهمون: Institut Català de la Salut, [Meric-Bernstam F] Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. [Bahleda R] Early Drug Development Department (DITEP), Gustave Roussy Cancer Center, Villejuif, France. [Hierro C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Sanson M] Sorbonne Université, Inserm, CNRS, UMR S 1127, Institut du Cerveau et de la Moelle Epinière, and AP-HP Hôpitaux Universitaires La Pitié Salpêtrière Charles Foix, Service de Neurologie 2 Mazarin, Paris, France. [Bridgewater J] UCL Cancer Institute, London, United Kingdom. [Arkenau HT] Sarah Cannon Research Institute, HCA Healthcare, London, United Kingdom, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Other subheadings::Other subheadings::/antagonists & inhibitors [Other subheadings], Nausea, medicine.medical_treatment, Otros calificadores::Otros calificadores::/farmacoterapia [Otros calificadores], Other subheadings::Other subheadings::/drug therapy [Other subheadings], Targeted therapy, neoplasias [ENFERMEDADES], Hyperphosphatemia, Breast cancer, Factors de creixement fibroblàstic - Receptors - Inhibidors, medicine, Otros calificadores::Otros calificadores::/antagonistas & inhibidores [Otros calificadores], Adverse effect, Intrahepatic Cholangiocarcinoma, Amino Acids, Peptides, and Proteins::Proteins::Membrane Proteins::Receptors, Cell Surface::Receptors, Peptide::Receptors, Growth Factor::Receptors, Fibroblast Growth Factor [CHEMICALS AND DRUGS], business.industry, aminoácidos, péptidos y proteínas::proteínas::proteínas de membranas::receptores de superficie celular::receptores de péptidos::receptores de factores de crecimiento::receptores de factores de crecimiento de fibroblastos [COMPUESTOS QUÍMICOS Y DROGAS], Càncer - Tractament, Cancer, medicine.disease, Neoplasms [DISEASES], Clinical research, Oncology, Cancer research, medicine.symptom, business

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2f30e7a5f313cb5684c095c734547b3
https://hdl.handle.net/11351/9694

4

Rectal neuroendocrine carcinoma: case report of a rare entity and perspective review of promising agents

المؤلفون: Monica Caro, Cinta Hierro, Ricard Mesia, Jose Luis Manzano, Cristina Buges, Laura Layos, Gabriela Antelo, Eduardo Baena, Juan Pablo Fernández

المصدر: Drugs in Context
Drugs in Context, Vol 9, Pp 1-13 (2020)

مصطلحات موضوعية: 0301 basic medicine, Oncology, medicine.medical_specialty, targeted agents, medicine.medical_treatment, gastro-enteropancreatic neuroendocrine neoplasms, Review, Disease, chemotherapy, Systemic therapy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, neuroendocrine carcinomas, Neuroendocrine carcinoma, molecular alterations, radiotherapy, Pharmacology, Chemotherapy, business.industry, lcsh:RM1-950, Rare entity, General Medicine, Immunotherapy, Neuroendocrine Carcinomas, gastro-entero-pancreatic neuroendocrine neoplasms, Radiation therapy, lcsh:Therapeutics. Pharmacology, 030104 developmental biology, 030220 oncology & carcinogenesis, Molecular Medicine, immunotherapy, business, epigenetic

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::18bc737e3f10c639e0955526e88ff04e
https://doi.org/10.7573/dic.2020-2-4

5

Multicenter Phase I Study of Erdafitinib (JNJ-42756493), Oral Pan-Fibroblast Growth Factor Receptor Inhibitor, in Patients with Advanced or Refractory Solid Tumors

المؤلفون: Cinta Hierro, Alain C. Mita, Andrés Cervantes, Mark M. Awad, Josep Tabernero, Italo Poggesi, Rastilav Bahleda, Victor Moreno, Nancy Chan, Antoine Italiano, Ademi E. Santiago-Walker, Trilok V. Parekh, Emiliano Calvo, Jeffrey R. Infante, Alexander I. Spira, Ramaswamy Govindan, Bob Zhong, Martha Gonzalez, Hong Xie

المصدر: Clinical Cancer Research. 25:4888-4897

مصطلحات موضوعية: Adult, Male, 0301 basic medicine, Cancer Research, medicine.medical_specialty, Administration, Oral, Antineoplastic Agents, Drug resistance, Gastroenterology, Young Adult, 03 medical and health sciences, Hyperphosphatemia, 0302 clinical medicine, Refractory, Erdafitinib, Neoplasms, Quinoxalines, Internal medicine, medicine, Humans, Neoplasm, Dosing, Adverse effect, Protein Kinase Inhibitors, Aged, Neoplasm Staging, Aged, 80 and over, business.industry, Genetic Variation, Middle Aged, Prognosis, medicine.disease, Receptors, Fibroblast Growth Factor, Treatment Outcome, 030104 developmental biology, Oncology, Tolerability, Drug Resistance, Neoplasm, 030220 oncology & carcinogenesis, Retreatment, Pyrazoles, Female, business

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfe6f93ed74fb1ed356ecce6401a4f2b
https://doi.org/10.1158/1078-0432.ccr-18-3334

6

Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials

المساهمون: Institut Català de la Salut, [Matos I, Carles J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain. [Villacampa G, Berché R, Pedrola A, Viaplana C, Dienstmann R] Oncology Data Science (OdysSey) Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Hierro C, Martin-Liberal J, Braña I, Azaro A, Vieito M, Saavedra O, Gardeazabal I, Hernando-Calvo A, Alonso G, Galvao V, Ochoa de Olza M, Ros J, Muñoz-Couselo E, Elez E, Rodon J, Saura C, Macarulla T, Oaknin A, Felip E, Garralda E] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. [Tabernero J] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Department of Medicine, UVic-UCC, Spain, Vall d'Hebron Barcelona Hospital Campus

المصدر: Scientia

مصطلحات موضوعية: Male, Oncology, Information Science::Informatics::Medical Informatics::Medical Informatics Applications [INFORMATION SCIENCE], Cancer Research, medicine.medical_specialty, Prognostic variable, Oncologia, Phases of clinical research, Ciencias de la información::informática::informática médica::aplicaciones de la informática médica [CIENCIA DE LA INFORMACIÓN], Medicina - Informàtica, Medical Oncology, Web tool, neoplasias [ENFERMEDADES], Patient Portals, Internal medicine, medicine, Humans, Selection (genetic algorithm), técnicas de investigación::métodos::diseño de la investigación::selección de los pacientes [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Aged, Clinical Trials as Topic, business.industry, Patient Selection, Middle Aged, Prognosis, Clinical trial, Neoplasms [DISEASES], Cohort, Prognostic model, Investigative Techniques::Methods::Research Design::Patient Selection [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Female, Early phase, business, Internet-Based Intervention, Assaigs clínics

وصف الملف: application/pdf

URL الوصول: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c6c8e375a408516cff89589a7095f1b9
https://hdl.handle.net/11351/7702

7

First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas

المؤلفون: Osama E. Rahma, Darren W.T. Lim, Ravit Geva, Toshikiko Doi, A. Xyrafas, Philippe L. Bedard, Jennifer Marie Mataraza, Alexander M. Lesokhin, Javier Otero, Tira Jing Ying Tan, Angad P Singh, Xinhui Chen, Jason J. Luke, Lisa Nardi, Sarina Anne Piha-Paul, Cinta Hierro

المساهمون: Institut Català de la Salut, [Piha-Paul SA] Department of Investigational Cancer Therapeutics, University of Texas MD Anderson Cancer Center, Houston, Texas, USA. [Geva R] Division of Oncology, Tel-Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel. [Tan TJ] Division of Medical Oncology, National Cancer Centre Singapore, Singapore. Department of Medicine, Division of Medical Oncology and Hematology, Princess Margaret Hospital Cancer Centre, Toronto, Ontario, Canada. [Lim DW] Division of Medical Oncology, National Cancer Centre Singapore, Singapore. [Hierro C] Servei d’Oncologia Mèdica, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Molecular Therapeutics Research Unit, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. [Doi T] Department of Experimental Therapeutics, National Cancer Center Hospital East, Kashiwa, Japan, Vall d'Hebron Barcelona Hospital Campus

المصدر: Journal for ImmunoTherapy of Cancer, Vol 9, Iss 8 (2021)
Journal for Immunotherapy of Cancer
Scientia

مصطلحات موضوعية: Male, Cancer Research, Lymphoma, Colorectal cancer, Gastroenterology, Antineoplastic Agents, Immunological, Neoplasms, Antineoplastic Combined Chemotherapy Protocols, Immunology and Allergy, antibodies, Immune Checkpoint Inhibitors, RC254-282, Clinical/Translational Cancer Immunotherapy, clinical trials as topic, Càncer - Tractament, terapéutica::terapéutica::farmacoterapia::protocolos antineoplásicos::terapéutica::farmacoterapia::protocolos de quimioterapia antineoplásica combinada [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Neoplasms::Neoplasms by Histologic Type::Lymphoma [DISEASES], Middle Aged, drug therapy, Oncology, Tolerability, Response Evaluation Criteria in Solid Tumors, Molecular Medicine, Adenocarcinoma, Female, Adult, medicine.medical_specialty, Maximum Tolerated Dose, Immunology, therapies, neoplasias::neoplasias por tipo histológico::linfoma [ENFERMEDADES], investigational, Antibodies, Monoclonal, Humanized, Quimioteràpia combinada, neoplasias [ENFERMEDADES], Pharmacokinetics, Therapeutics::Therapeutics::Drug Therapy::Antineoplastic Protocols::Therapeutics::Drug Therapy::Antineoplastic Combined Chemotherapy Protocols [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Internal medicine, Glucocorticoid-Induced TNFR-Related Protein, medicine, Humans, Adverse effect, Aged, Pharmacology, combination, Dose-Response Relationship, Drug, business.industry, Endometrial cancer, Cancer, medicine.disease, Neoplasms [DISEASES], business, neoplasm